Murraya koenigii leaf extract inhibits proteasome activity and induces cell death in breast cancer cells

BMC Complementary and Alternative Medicine

Volumn 13, Issue , 2013, Pages

  Noolu, Bindu ^a   Ajumeera, Rajanna ^a   Chauhan, Anitha ^a   Nagalla, Balakrishna ^a   Manchala, Raghunath ^a   Ismail, Ayesha ^a  

^a NATIONAL INSTITUTE OF NUTRITION   (India)

Author keywords

26S proteasome; Breast cancer; Methanolic extract; Murraya koenigii; Polyphenols; Proteasome inhibitor

Indexed keywords

MURRAYA KOENIGII EXTRACT; PHENOL DERIVATIVE; PROTEASOME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL MDA MB 231; CANCER INHIBITION; CELL DEATH; CELL LINE; CELL STRAIN MCF 7; CELL VIABILITY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG FIBROBLAST; MURRAYA KOENIGII; PLANT LEAF; S PHASE CELL CYCLE CHECKPOINT;

ANNEXIN A5; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MURRAYA; PHYTOTHERAPY; PLANT EXTRACTS; PLANT LEAVES; POLYPHENOLS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; S PHASE;

EID: 84872033874     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-13-7     Document Type: Article

References (51)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan. Int J Cancer 2000, 94:153-156.
2. Pruthi JS. Spices and condiments 1976, New Delhi: National Book Trust India.
3. Chevallier A. The encyclopedia of medicinal plants 1996, London: Dorlon Kindersley Publisher.
4. Sivarajan VV, Balachandran I. Ayurvedic drugs and their plant sources 1994, New Delhi: Oxford & IBH Publishing.
5. Muthumani P, Venkatraman S, Ramseshu KV, Meera R, Devi P, Kameswari B. Pharmacological studies of anticancer, anti inflammatory activities of Murraya koenigii (Linn) Spreng in experimental animals. J Pharm Sci Res 2009, 1:137-141.
6. Nayak A, Banerji J, Banerji A, Mandal S. Review on chemistry and pharmacology of Murraya koenigii Spreng (Rutaceae). J Chem Pharm Res 2010, 2:286-299.
7. Kesari AN, Kesari S, Singh SK, Gupta RK, Watal G. Studies on the glycemic and lipidemic effect of Murraya koenigii in experimental animals. J Ethnopharmacol 2007, 112(2):305-311. 10.1016/j.jep.2007.03.023, 17467937.
8. Arulselvan P, Senthilkumar GP, Sathish Kumar D, Subramanian S. Anti-diabetic effect of Murraya koenigii leaves on streptozotocin induced diabetic rats. Pharmazie 2006, 61(10):874-877.
9. Lawal HA, Atiku MK, Khelpai DG. Hypoglycaemic and hypolipidemic effect of aqueous leaf extract of Murraya koenigii in normal and alloxan-diabetic rats. Niger J Physiol Sci 2008, 23(1-2):37-40.
10. Gupta S, Prakash J. Studies on Indian green leafy vegetables for their antioxidant activity. Plant Foods Hum Nutr 2009, 64(1):39-45. 10.1007/s11130-008-0096-6, 18985454.
11. Tachibana Y, Kikuzaki H, Lajis NH, Nakatani N. Antioxidative activity of carbazoles from Murraya koenigii leaves. J Agric Food Chem 2001, 49(11):5589-5594. 10.1021/jf010621r, 11714364.
12. Khan BA, Abraham A, Leelamma S. Anti-oxidant effects of curry leaf, Murraya koenigii and mustard seeds, Brassica juncea in rats fed with high fat diet. Indian J Exp Biol 1997, 35(2):148-150.
13. Adebajo AC, Ayoola OF, Iwalewa EO, Akindahunsi AA, Omisore NO, Adewunmi CO, Adenowo TK. Anti-trichomonal, biochemical and toxicological activities of methanolic extract and some carbazole alkaloids isolated from the leaves of Murraya koenigii growing in Nigeria. Phytomedicine 2006, 13(4):246-254. 10.1016/j.phymed.2004.12.002, 16492527.
14. Mandal S, Nayak A, Kar M, Banerjee SK, Das A, Upadhyay SN, Singh RK, Banerji A, Banerji J. Antidiarrheal activity of carbazole alkaloids from Murraya koenigii Spreng (Rutaceae) seeds. Fitoterapia 2010, 81(1):72-74. 10.1016/j.fitote.2009.08.016, 19695314.
15. Xie JT, Chang WT, Wang CZ, Mehendale SR, Li J, Ambihaipahar R, Ambihaipahar U, Fong HH, Yuan CS. Curry leaf (Murraya koenigii Spreng.) reduces blood cholesterol and glucose levels in ob/ob mice. Am J Chin Med 2006, 34(2):279-284. 10.1142/S0192415X06003825, 16552838.
16. Gupta S, George M, Singhal M, Sharma GN, Garg V. Leaves extract of murraya koenigii linn for anti-inflammatory and analgesic activity in animal models. J Adv Pharm Technol Res 2010, 1(1):68-77. 3255384, 22247833.
17. Shah AS, Wakade AS, Juvekar AR. Immunomodulatory activity of methanolic extract of Murraya koenigii (L) Spreng. Leaves. Indian J Exp Biol 2008, 46(7):505-509.
18. Ito C, Itoigawa M, Nakao K, Murata T, Tsuboi M, Kaneda N, Furukawa H. Induction of apoptosis by carbazole alkaloids isolated from Murraya koenigii. Phytomedicine 2006, 13(5):359-365. 10.1016/j.phymed.2005.03.010, 16635744.
19. Roy MK, Thalang VN, Trakoontivakorn G, Nakahara K. Mechanism of mahanine-induced apoptosis in human leukemia cells (HL-60). Biochem Pharmacol 2004, 67(1):41-51. 10.1016/j.bcp.2003.07.021, 14667927.
20. Bhattacharya K, Samanta SK, Tripathi R, Mallick A, Chandra S, Pal BC, Shaha C, Mandal C. Apoptotic effects of mahanine on human leukemic cells are mediated through crosstalk between Apo-1/Fas signaling and the Bid protein and via mitochondrial pathways. Biochem Pharmacol 2010, 79(3):361-372. 10.1016/j.bcp.2009.09.007, 19751707.
21. Ayesha I, Bindu N, Shulagna S, Chandana M, Mehrajuddin B, Raghunath M. Proteasome inhibitory potential of commonly consumed dietary ingredients. Int J Food Nutr Sci 2012, 1(4):27-31.
22. Scalbert A, Manach C, Morand C, Rémésy C, Jiménez L. Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr 2005, 45(4):287-306. Review, 10.1080/1040869059096, 16047496.
23. Scalbert A, Johnson IT, Saltmarsh M. Polyphenols: antioxidants and beyond. Am J Clin Nutr 2005, 81(Suppl 1):215S-217S. Review.
24. Chen D, Daniel KG, Chen MS, Kuhn DJ, Landis-Piwowar KR, Dou QP. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem Pharmacol 2005, 69(10):1421-1432. 10.1016/j.bcp.2005.02.022, 15857606.
25. Pettinari A, Amici M, Cuccioloni M, Angeletti M, Fioretti E, Eleuteri AM. Effect of polyphenolic compounds on the proteolytic activities of constitutive and immuno-proteasomes. Antioxid Redox Signal 2006, 8(1-2):121-129.
26. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998, 67:425-479. Review, 10.1146/annurev.biochem.67.1.425, 9759494.
27. Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, Huber R. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997, 386:463-471. 10.1038/386463a0, 9087403.
28. Rivett AJ. The multicatalytic proteinase. Multiple proteolytic activities. J Biol Chem 1989, 264(21):12215-12219.
29. Jung T, Bader N, Grune T. Oxidized proteins: intracellular distribution and recognition by the proteasome. Arch Biochem Biophys 2007, 462(2):231-237. Review, 10.1016/j.abb.2007.01.030, 17362872.
30. Tambyrajah WS, Bowler LD, Medina-Palazon C, Sinclair AJ. Cell cycle-dependent caspase-like activity that cleaves p27(KIP1) is the beta(1) subunit of the 20S proteasome. Arch Biochem Biophys 2007, 466(2):186-193. 10.1016/j.abb.2007.07.019, 17854759.
31. Chen WJ, Lin JK. Induction of G1 arrest and apoptosis in human jurkat T cells by pentagalloylglucose through inhibiting proteasome activity and elevating p27Kip1, p21Cip1/WAF1, and Bax proteins. J Biol Chem 2004, 279(14):13496-13505. 10.1074/jbc.M212390200, 14726525.
32. Hilt W, Wolf DH. Proteasomes: The World of Regulatory Proteolysis 2000, Georgetown, Texas: Landes Bioscience.
33. Goldberg AL. Functions of the proteasome: the lysis at the end of the tunnel. Science 1995, 268(5210):522-523. Review, 10.1126/science.7725095, 7725095.
34. Hochstrasser M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 1995, 7(2):215-223. Review, 10.1016/0955-0674(95)80031-X, 7612274.
35. Singleton VL, Orthofer R, Lamuela-Raventos RM. Analysis of total phenols and other oxidation substrates and antioxidants by means of Folin-Ciocalteu Reagent. Methods Enzymol 1999, 299:152-178.
36. Adams M, Jewell AP. The use of complementary and alternative medicine by cancer patients. Int Semin Surg Oncol 2007, 4:10. 10.1186/1477-7800-4-10, 1872026, 17470282.
37. Wada M, Kosaka M, Saito S, Sano T, Tanaka K, Ichihura A. Serum concentrations and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance. J Lab Clin Med 1993, 121:215-223.
38. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 2000, 97(8):3850-3855. 10.1073/pnas.070047997, 18105, 10725400.
39. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998, 5(12):1062-1075. 10.1038/sj.cdd.4400436, 9894613.
40. Dou QP, Li B. Proteasome inhibitors as potential novel anticancer agents. Drug Resist Update 1999, 2(4):215-223.
41. Kazi A, Urbizu DA, Kuhn DJ, Acebo AL, Jackson ER, Greenfelder GP, Kumar NB, Dou QP. A natural musaceas plant extract inhibits proteasome activity and induces apoptosis selectively in human tumor and transformed, but not normal and non-transformed, cells. Int J Mol Med 2003, 12(6):879-887.
42. Landis-Piwowar KR, Milacic V, Chen D, Yang H, Zhao Y, Chan TH, Yan B, Dou QP. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Update 2006, 9(6):263-273. Review.
43. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003, 29(Suppl 1):3-9. Review.
44. Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003, 10(5):361-369. Review.
45. Richardson PG, Anderson KC. Bortezomib: a novel therapy approved for multiple myeloma. Clin Adv Hematol Oncol 2003, 1(10):596-600. Review.
46. Delic J, Masdehors P, Omura S, Cosset JM, Dumont J, Binet JL, Magdelénat H. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radio resistant human chronic lymphocytic leukemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 1998, 77(7):1103-1107. 10.1038/bjc.1998.183, 2150120, 9569046.
47. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA, Berenson JR. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003, 9(3):1136-1144.
48. Kandaswami C, Lee LT, Lee PP, Hwang JJ, Ke FC, Huang YT, Lee MT. The antitumor activities of flavonoids. In Vivo 2005, 19:895-909.
49. Thomasset SC, Berry DP, Garcea G, Marczylo T, Steward WP, Gescher J. Dietary polyphenolic phytochemicals - promising cancer chemopreventive agents in humans? A review of their clinical properties. Int J Cancer 2007, 120:451-458. 10.1002/ijc.22419, 17131309.
50. Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001, 276(16):13322-13330. 10.1074/jbc.M004209200, 11278274.
51. Kuhn DJ, Lam WH, Kazi A, Daniel KG, Sung S, Chow LMC, Chan TH, Dou QP. Synthetic peracetate tea polyphenols as potent proteasome inhibitors and apoptosis inducers in human cancer cells. Front Bio 2005, 10:1010-1023.